Free Trial

Cardlytics, Inc. (NASDAQ:CDLX) Given Consensus Recommendation of "Hold" by Analysts

Cardlytics logo with Business Services background

Shares of Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) have received a consensus rating of "Hold" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $6.42.

A number of research analysts recently commented on the company. Needham & Company LLC reissued a "hold" rating on shares of Cardlytics in a research note on Thursday, March 13th. Lake Street Capital lowered their price target on shares of Cardlytics from $5.00 to $3.00 and set a "hold" rating for the company in a report on Thursday, March 13th. Finally, Evercore ISI cut their price objective on Cardlytics from $4.00 to $3.00 and set an "in-line" rating on the stock in a research report on Thursday, March 13th.

Read Our Latest Report on CDLX

Cardlytics Price Performance

NASDAQ:CDLX remained flat at $1.50 during mid-day trading on Tuesday. 1,186,923 shares of the company traded hands, compared to its average volume of 1,015,818. Cardlytics has a 12 month low of $1.22 and a 12 month high of $15.89. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. The company has a market cap of $78.13 million, a P/E ratio of -0.25 and a beta of 1.39. The firm's 50-day moving average is $2.19 and its 200-day moving average is $3.16.

Insider Buying and Selling

In other news, CFO Alexis Desieno sold 24,778 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $84,245.20. Following the transaction, the chief financial officer now directly owns 140,948 shares in the company, valued at $479,223.20. The trade was a 14.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Amit Gupta sold 46,857 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $159,313.80. Following the completion of the transaction, the chief executive officer now directly owns 418,637 shares of the company's stock, valued at approximately $1,423,365.80. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 90,172 shares of company stock valued at $313,759. Company insiders own 4.40% of the company's stock.

Institutional Trading of Cardlytics

A number of institutional investors have recently bought and sold shares of the stock. Mirabella Financial Services LLP purchased a new stake in shares of Cardlytics in the fourth quarter worth approximately $4,285,000. D. E. Shaw & Co. Inc. increased its stake in Cardlytics by 97.4% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,131,505 shares of the company's stock worth $4,198,000 after purchasing an additional 558,235 shares during the period. Rangeley Capital LLC bought a new stake in shares of Cardlytics during the fourth quarter worth $1,187,000. RBF Capital LLC boosted its stake in shares of Cardlytics by 64.7% during the fourth quarter. RBF Capital LLC now owns 803,763 shares of the company's stock valued at $2,982,000 after purchasing an additional 315,635 shares during the period. Finally, Millennium Management LLC bought a new position in shares of Cardlytics in the fourth quarter worth about $535,000. 68.10% of the stock is currently owned by institutional investors.

Cardlytics Company Profile

(Get Free Report

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Read More

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Should You Invest $1,000 in Cardlytics Right Now?

Before you consider Cardlytics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.

While Cardlytics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Markets in Rally Mode: Will Earnings Keep It Going?
3 Tech Stocks to Buy Now—And 3 You’ll Regret Keeping
After Stellar Earnings, Is TSMC the Next Chip Leader?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines